|
|
选择性组蛋白去乙酰化酶抑制剂的研究进展
|
Abstract:
| [1] | Zhao, C., Dong, H., Xu, Q., et al. (2020) Histone Deacetylase (HDAC) Inhibitors in Cancer: A Patent Review (2017-Present). Expert Opinion on Therapeutic Patents, 30, 263-274. https://doi.org/10.1080/13543776.2020.1725470 |
| [2] | Sultana, F., Manasa, K.L., Shaik, S.P., et al. (2019) Zinc Dependent Histone Deacetylase Inhibitors in Cancer Therapeutics: Recent Update. Current Medicinal Chemistry, 26, 7212-7280.
https://doi.org/10.2174/0929867325666180530094120 |
| [3] | Zhang, H., Shang, Y.P., Chen, H.Y., et al. (2017) Histone Deacetylase Function as Novel Potential Therapeutic Targets for Cancer. Hepatology Research, 47, 149-159. https://doi.org/10.1111/hepr.12757 |
| [4] | Zhao, C., Zang, J., Ding, Q., et al. (2018) Discovery of Meta-Sulfamoyl N-Hydroxybenzamides as HDAC8 Selective Inhibitors. European Journal of Medicinal Chemistry, 150, 282-291. https://doi.org/10.1016/j.ejmech.2018.03.002 |
| [5] | Parra, M. (2015) Class IIa HDACs—New Insights into Their Functions in Physiology and Pathology. The FEBS Journal, 282, 1736-1744. https://doi.org/10.1111/febs.13061 |
| [6] | Li, T., Zhang, C., Hassan, S., et al. (2018) Histone Deacetylase 6 in Cancer. Journal of Hematology & Oncology, 11, 111. https://doi.org/10.1186/s13045-018-0654-9 |
| [7] | Yue, L., Sharma, V., Horvat, N.P., et al. (2020) HDAC11 Deficiency Disrupts Oncogene-Induced Hematopoiesis in Myeloproliferative Neoplasms. Blood, 135, 191-207. https://doi.org/10.1182/blood.2019895326 |
| [8] | Thomas, A.M., David, J.W. and Sandro, B. (2003) Histone Deacetylase Inhibitors. Journal of Medicinal Chemistry, 46, 5097-5116. https://doi.org/10.1021/jm0303094 |
| [9] | Marson, C.M. (2009) Histone Deacetylase Inhibitors: Design, Structure-Activity Relationships and Therapeutic Implications for Cancer. Anti-Cancer Agents in Medicinal Chemistry, 9, 661-692.
https://doi.org/10.2174/187152009788679976 |
| [10] | Luan, Y., Li, J., Bernatchez, J.A., et al. (2019) Kinase and Histone Deacetylase Hybrid Inhibitors for Cancer Therapy. Journal of Medicinal Chemistry, 62, 3171-3183. https://doi.org/10.1021/acs.jmedchem.8b00189 |
| [11] | Hess-Stumpp, H. (2005) Histone Deacetylase Inhibitors and Cancer: From Cell Biology to the Clinic. European Journal of Cell Biology, 84, 109-121. https://doi.org/10.1016/j.ejcb.2004.12.010 |
| [12] | Trapani, D., Esposito, A., Criscitiello, C., et al. (2017) Entinostat for the Treatment of Breast Cancer. Expert Opinion on Investigational Drugs, 26, 965-971. https://doi.org/10.1080/13543784.2017.1353077 |
| [13] | Fournel, M., Bonfils, C., Hou, Y., et al. (2008) MGCD0103, a Novel Isotype-Selective Histone Deacetylase Inhibitor, Has Broad Spectrum Antitumor Activity in Vitro and in Vivo. Molecular Cancer Therapeutics, 7, 759-768.
https://doi.org/10.1158/1535-7163.MCT-07-2026 |
| [14] | Graziano, M.J., Spoon, T.A., Cockrell, E.A., et al. (2001) Induction of Apoptosis in Rat Peripheral Blood Lymphocytes by the Anticancer Drug CI-994 (Acetyldinaline). Journal of Biomedicine and Biotechnology, 1, 52-61.
https://doi.org/10.1155/S1110724301000146 |
| [15] | Beckers, T., Burkhardt, C., Wieland, H., et al. (2007) Distinct Pharmacological Properties of Second Generation HDAC Inhibitors with the Benzamide or Hydroxamate Head Group. International Journal of Cancer, 121, 1138-1148.
https://doi.org/10.1002/ijc.22751 |
| [16] | Henning, S.W. (2010) 178 Preclinical Characterization of 4SC-202, a Novel Isotype Specific HDAC Inhibitor. European Journal of Cancer—Supplement, 8, 61. https://doi.org/10.1016/S1359-6349(10)71883-8 |
| [17] | Peng, X., Liao, G., Sun, P., et al. (2019) An Overview of HDAC Inhibitors and Their Synthetic Routes. Current Topics in Medicinal Chemistry, 19, 1005-1040. https://doi.org/10.2174/1568026619666190227221507 |
| [18] | Ralph, M. (2015) Inhibitors of Histone Deacetylase. PCT International Application, 2015069693, May 14. |
| [19] | Tang, S., Cheng, B., Zhe, N., et al. (2018) Histone Deacetylase Inhibitor BG45-Mediated HO-1 Expression Induces Apoptosis of Multiple Myeloma Cells by the JAK2/STAT3 Pathway. Anticancer Drugs, 29, 61-74.
https://doi.org/10.1097/CAD.0000000000000568 |
| [20] | Malvaez, M., McQuown, S.C., Rogge, G.A., et al. (2013) HDAC3-Selective Inhibitor Enhances Extinction of Cocaine- Seeking Behavior in a Persistent Manner. Proceedings of the National Academy of Sciences of the United States of America, 110, 2647-2652. https://doi.org/10.1073/pnas.1213364110 |
| [21] | Zhang, M.J., Zhao, Q.C., Xia, M.X., et al. (2020) The HDAC3 Inhibitor RGFP966 Ameliorated Ischemic Brain Damage by Downregulating the AIM2 Inflammasome. The FASEB Journal, 34, 648-662.
https://doi.org/10.1096/fj.201900394RRR |
| [22] | Wagner, F.F., Lundh, M., Kaya, T., et al. (2016) An Isochemogenic Set of Inhibitors to Define the Therapeutic Potential of Histone Deacetylases in β-Cell Protection. ACS Chemical Biology, 11, 363-374.
https://doi.org/10.1021/acschembio.5b00640 |
| [23] | Wagner, F.F., Zhang, Y.L., Fass, D.M., et al. (2015) Kinetically Selective Inhibitors of Histone Deacetylase 2 (HDAC2) as Cognition Enhancers. Chemical Science, 6, 804-815. https://doi.org/10.1039/C4SC02130D |
| [24] | Hirata, Y., Sasaki, T., Kanki, H., et al. (2018) New 5-Aryl-Substituted 2-Aminobenzamide-Type HDAC Inhibitors with a Diketopiperazine Group and Their Ameliorating Effects on Ischemia-Induced Neuronal Cell Death. Scientific Reports, 8, Article No. 1400. https://doi.org/10.1038/s41598-018-19664-9 |
| [25] | Mendoza-Sanchez, R., Cotnoir-White, D., Kulpa, J., et al. (2015) Design, Synthesis and Evaluation of Antiestrogen and Histone Deacetylase Inhibitor Molecular Hybrids. Bioorganic & Medicinal Chemistry, 23, 7597-7606.
https://doi.org/10.1016/j.bmc.2015.11.005 |
| [26] | Boissinot, M., Inman, M., Hempshall, A., et al. (2012) Induction of Differentiation and Apoptosis in Leukaemic Cell Lines by the Novel Benzamide Family Histone Deacetylase 2 and 3 Inhibitor MI-192. Leukemia Research, 36, 1304-1310.
https://doi.org/10.1016/j.leukres.2012.07.002 |
| [27] | Eyre, T.A., Collins, G.P., Gupta, A., et al. (2019) A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of CXD101 in Patients with Advanced Cancer. Cancer, 125, 99-108. https://doi.org/10.1002/cncr.31791 |
| [28] | Poli, G., Di Fabio, R., Ferrante, L., et al. (2017) Largazole Analogues as Histone Deacetylase Inhibitors and Anticancer Agents: An Overview of Structure-Activity Relationships. ChemMedChem, 12, 1917-1926.
https://doi.org/10.1002/cmdc.201700563 |
| [29] | Ma, N., Luo, Y., Wang, Y., et al. (2016) Selective Histone Deacetylase Inhibitors with Anticancer Activity. Current Topics in Medicinal Chemistry, 16, 415-426. https://doi.org/10.2174/1568026615666150813145629 |
| [30] | Parlet, C.P., Kavanaugh, J.S., Crosby, H.A., et al. (2019) Apicidin Attenuates MRSA Virulence through Quorum-Sensing Inhibition and Enhanced Host Defense. Cell Reports, 27, 187-198.e6.
https://doi.org/10.1016/j.celrep.2019.03.018 |
| [31] | Arts, J., King, P., Mari？n, A., et al. (2009) JNJ-26481585, a Novel “Second-Generation” Oral Histone Deacetylase Inhibitor, Shows Broad-Spectrum Preclinical Antitumoral Activity. Clinical Cancer Research, 15, 6841-6851.
https://doi.org/10.1158/1078-0432.CCR-09-0547 |
| [32] | Su, G.H., Sohn, T.A., Ryu, B., et al. (2000) A Novel Histone Deacetylase Inhibitor Identified by High-Throughput Transcriptional Screening of a Compound Library. Cancer Research, 60, 3137-3142. |
| [33] | Sharma, V., Koul, N., Joseph, C., et al. (2010) HDAC Inhibitor, Scriptaid, Induces Glioma Cell Apoptosis through JNK Activation and Inhibits Telomerase Activity. Journal of Cellular and Molecular Medicine, 14, 2151-2161.
https://doi.org/10.1111/j.1582-4934.2009.00844.x |
| [34] | Wood, T.E., Dalili, S., Simpson, C.D., et al. (2010) Selective Inhibition of Histone Deacetylases Sensitizes Malignant Cells to Death Receptor Ligands. Molecular Cancer Therapeutics, 9, 246-256.
https://doi.org/10.1158/1535-7163.MCT-09-0495 |
| [35] | McCourt, C., Maxwell, P., Mazzucchelli, R., et al. (2012) Elevation of c-FLIP in Castrate-Resistant Prostate Cancer Antagonizes Therapeutic Response to Androgen Receptor-Targeted Therapy. Clinical Cancer Research, 18, 3822-3833.
https://doi.org/10.1158/1078-0432.CCR-11-3277 |
| [36] | Balasubramanian, S., Ramos, J., Luo, W., et al. (2008) A Novel Histone Deacetylase 8 (HDAC8)-Specific Inhibitor PCI-34051 Induces Apoptosis in T-Cell Lymphomas. Leukemia, 22, 1026-1034. https://doi.org/10.1038/leu.2008.9 |
| [37] | Suzuki, T., Muto, N., Bando, M., et al. (2014) Design, Synthesis, and Biological Activity of NCC149 Derivatives as Histone Deacetylase 8-Selective Inhibitors. ChemMedChem, 9, 657-664. https://doi.org/10.1002/cmdc.201300414 |
| [38] | Tng, J., Lim, J., Wu, K.C., et al. (2020) Achiral Derivatives of Hydroxamate AR-42 Potently Inhibit Class I HDAC Enzymes and Cancer Cell Proliferation. Journal of Medicinal Chemistry, 63, 5956-5971.
https://doi.org/10.1021/acs.jmedchem.0c00230 |
| [39] | Hassan, M.M., Israelian, J., Nawar, N., et al. (2020) Characterization of Conformationally Constrained Benzanilide Scaffolds for Potent and Selective HDAC8 Targeting. Journal of Medicinal Chemistry, 63, 8634-8648.
https://doi.org/10.1021/acs.jmedchem.0c01025 |
| [40] | Yang, Y.C., Chen, C.N., Wu, C.I., et al. (2013) NBM-T-L-BMX-OS01, Semisynthesized from Osthole, Is a Novel Inhibitor of Histone Deacetylase and Enhances Learning and Memory in Rats. Evidence-Based Complementary and Alternative Medicine, 2013, Article ID: 514908. https://doi.org/10.1155/2013/514908 |
| [41] | Moffat, D., Patel, S., Day, F., et al. (2010) Discovery of 2-(6-{[(6-fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex- 3-yl)-N-hydroxypyrim Idine-5-carboxamide (CHR-3996), a Class I Selective Orally Active Histone Deacetylase Inhibitor. Journal of Medicinal Chemistry, 53, 8663-8678. https://doi.org/10.1021/jm101177s |
| [42] | Marek, L., Hamacher, A., Hansen, F.K., et al. (2013) Histone Deacetylase (HDAC) Inhibitors with a Novel Connecting Unit Linker Region Reveal a Selectivity Profile for HDAC4 and HDAC5 with Improved Activity against Chemoresistant Cancer Cells. Journal of Medicinal Chemistry, 56, 427-436. https://doi.org/10.1021/jm301254q |
| [43] | Di Giorgio, E., Gagliostro, E. and Brancolini, C. (2015) Selective Class IIa HDAC Inhibitors: Myth or Reality. Cellular and Molecular Life Sciences, 72, 73-86. https://doi.org/10.1007/s00018-014-1727-8 |
| [44] | Olsson, A., Bj？rk, A., Vallon-Christersson, J., et al. (2010) Tasquinimod (ABR-215050), a Quinoline-3-Carboxamide Anti-Angiogenic Agent, Modulates the Expression of Thrombospondin-1 in Human Prostate Tumors. Molecular Cancer, 9, 107. https://doi.org/10.1186/1476-4598-9-107 |
| [45] | Mai, A., Massa, S., Pezzi, R., et al. (2005) Class II (IIa)-Selective Histone Deacetylase Inhibitors. 1. Synthesis and Biological Evaluation of Novel (Aryloxopropenyl)pyrrolyl Hydroxyamides. Journal of Medicinal Chemistry, 48, 3344-3353. https://doi.org/10.1021/jm049002a |
| [46] | Butler, K.V., Kalin, J., Brochier, C., et al. (2010) Rational Design and Simple Chemistry Yield a Superior, Neuroprotective HDAC6 Inhibitor, Tubastatin A. Journal of the American Chemical Society, 132, 10842-10846.
https://doi.org/10.1021/ja102758v |
| [47] | Haggarty, S.J., Koeller, K.M., Wong, J.C., et al. (2003) Domain-Selective Small-Molecule Inhibitor of Histone Deacetylase 6 (HDAC6)-Mediated Tubulin Deacetylation. Proceedings of the National Academy of Sciences of the United States of America, 100, 4389-4394. https://doi.org/10.1073/pnas.0430973100 |
| [48] | Tan, J., Cang, S., Ma, Y., et al. (2010) Novel Histone Deacetylase Inhibitors in Clinical Trials as Anti-Cancer Agents. Journal of Hematology & Oncology, 3, 5. https://doi.org/10.1186/1756-8722-3-5 |
| [49] | Jochems, J., Boulden, J., Lee, B.G., et al. (2014) Antidepressant-Like Properties of Novel HDAC6-Selective Inhibitors with Improved Brain Bioavailability. Neuropsychopharmacology, 39, 389-400. https://doi.org/10.1038/npp.2013.207 |
| [50] | Kozikowski, A.P., Tapadar, S., Luchini, D.N., et al. (2008) Use of the Nitrile Oxide Cycloaddition (NOC) Reaction for Molecular Probe Generation: A New Class of Enzyme Selective Histone Deacetylase Inhibitors (HDACIs) Showing Picomolar Activity at HDAC6. Journal of Medicinal Chemistry, 51, 4370-4373. https://doi.org/10.1021/jm8002894 |
| [51] | Lee, J.H., Mahendran, A., Yao, Y., et al. (2013) Development of a Histone Deacetylase 6 Inhibitor and Its Biological Effects. Proceedings of the National Academy of Sciences of the United States of America, 110, 15704-15709.
https://doi.org/10.1073/pnas.1313893110 |
| [52] | Bergman, J.A., Woan, K., Perez-Villarroel, P., et al. (2012) Selective Histone Deacetylase 6 Inhibitors Bearing Substituted Urea Linkers Inhibit Melanoma Cell Growth. Journal of Medicinal Chemistry, 55, 9891-9899.
https://doi.org/10.1021/jm301098e |
| [53] | Hideshima, T., Qi, J., Paranal, R.M., et al. (2016) Discovery of Selective Small-Molecule HDAC6 Inhibitor for Overcoming Proteasome Inhibitor Resistance in Multiple Myeloma. Proceedings of the National Academy of Sciences of the United States of America, 113, 13162-13167. https://doi.org/10.1073/pnas.1608067113 |
| [54] | Inks, E.S., Josey, B.J., Jesinkey, S.R., et al. (2012) A Novel Class of Small Molecule Inhibitors of HDAC6. ACS Chemical Biology, 7, 331-339. https://doi.org/10.1021/cb200134p |
| [55] | Wagner, F.F., Olson, D.E., Gale, J.P., et al. (2013) Potent and Selective Inhibition of Histone Deacetylase 6 (HDAC6) Does Not Require a Surface-Binding Motif. Journal of Medicinal Chemistry, 56, 1772-1776.
https://doi.org/10.1021/jm301355j |
| [56] | Kozikowski, A.P., Shen, S., Pardo, M., et al. (2019) Brain Penetrable Histone Deacetylase 6 Inhibitor SW-100 Ameliorates Memory and Learning Impairments in a Mouse Model of Fragile X Syndrome. ACS Chemical Neuroscience, 10, 1679-1695. https://doi.org/10.1021/acschemneuro.8b00600 |
| [57] | Shen, S., Hadley, M., Ustinova, K., et al. (2019) Discovery of a New Isoxazole-3-hydroxamate-Based Histone Deacetylase 6 Inhibitor SS-208 with Antitumor Activity in Syngeneic Melanoma Mouse Models. Journal of Medicinal Chemistry, 62, 8557-8577. https://doi.org/10.1021/acs.jmedchem.9b00946 |
| [58] | Vergani, B., Sandrone, G., Marchini, M., et al. (2019) Novel Benzohydroxamate-Based Potent and Selective Histone Deacetylase 6 (HDAC6) Inhibitors Bearing a Pentaheterocyclic Scaffold: Design, Synthesis, and Biological Evaluation. Journal of Medicinal Chemistry, 62, 10711-10739. https://doi.org/10.1021/acs.jmedchem.9b01194 |
| [59] | Martin, M.W., Lee, J.Y., Lancia, D.R., et al. (2018) Discovery of Novel N-Hydroxy-2-Arylisoindoline-4-Carbox- amides as Potent and Selective Inhibitors of HDAC11. Bioorganic & Medicinal Chemistry Letters, 28, 2143-2147.
https://doi.org/10.1016/j.bmcl.2018.05.021 |
| [60] | Son, S.I., Cao, J., Zhu, C.L., et al. (2019) Activity-Guided Design of HDAC11-Specific Inhibitors. ACS Chemical Biology, 14, 1393-1397. https://doi.org/10.1021/acschembio.9b00292 |
